Table 4 Percentage of incidences of adverse events at months 1, 3 and 6 following treatment with erenumab in the overall population of patients treated with erenumab
From: A prospective real-world analysis of erenumab in refractory chronic migraine
Month 1 (N = 162) N (%) | Month 3 (N = 100) N (%) | Month 6 (N = 73) N (%) | |
|---|---|---|---|
Constipation | 32 (20%) | 11 (11%) | 4 (5%) |
Cold-flu/like | 25 (15%) | 8 (8%) | 2 (3%) |
Generalised aches/pain | 10 (6%) | 1 (1%) | 1 (1%) |
Itchiness | 8 (5%) | 1 (1%) | 1 (1%) |
Injection site reaction (pain/skin redness) | 5 (3%) | 0 (0%) | 1 (1%) |
Muscle spasms | 3 (2%) | 0 (0%) | 0 (0%) |
Others | 15 (9%) | 4 (4%) | 3 (4%) |